Pfizer (PFE) Current Taxes (2009 - 2026)

Pfizer (PFE) has reported Current Taxes for 18 consecutive years, with $653.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Taxes fell 82.23% year-over-year to $653.0 million in Q2 2026; TTM through Jun 2026 was $653.0 million, a 82.23% decrease from a year earlier, with the FY2025 full-year figure at $3.1 billion, up 6.63% from the prior year.
• Current Taxes was $653.0 million for Q2 2026 at Pfizer, down from $3.1 billion in the prior quarter.
• Over five years, Current Taxes peaked at $3.8 billion in Q3 2025 and troughed at $653.0 million in Q2 2026.
• A 5-year average of $2.8 billion and a median of $3.0 billion in 2023 frame the typical range for Current Taxes.
• Across the five-year window, Current Taxes soared 126.77% in 2022 and tumbled 82.23% in 2026, its largest moves.
• Over 5 years, Current Taxes stood at $1.6 billion in 2022, then soared by 48.02% to $2.3 billion in 2023, then increased by 23.88% to $2.9 billion in 2024, then grew by 6.63% to $3.1 billion in 2025, then sank by 78.96% to $653.0 million in 2026.
• The last three Current Taxes figures came in at $653.0 million (Q2 2026), $3.1 billion (Q1 2026), and $3.1 billion (Q4 2025), per Business Quant data.